503 related articles for article (PubMed ID: 24418474)
1. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
3. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
[TBL] [Abstract][Full Text] [Related]
4. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
5. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
7. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Yi GZ; Liu YW; Xiang W; Wang H; Chen ZY; Xie SD; Qi ST
J Neurol Sci; 2016 Aug; 367():101-6. PubMed ID: 27423571
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
Smalley S; Chalmers AJ; Morley SJ
Mol Cancer; 2014 Jun; 13():144. PubMed ID: 24909675
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
Han TJ; Cho BJ; Choi EJ; Kim DH; Song SH; Paek SH; Kim IA
J Neurooncol; 2016 Oct; 130(1):89-98. PubMed ID: 27510952
[TBL] [Abstract][Full Text] [Related]
10. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
11. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
12. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
15. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Chen CC; Taniguchi T; D'Andrea A
J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
[TBL] [Abstract][Full Text] [Related]
16. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
17. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
18. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
[TBL] [Abstract][Full Text] [Related]
19. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
20. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
